4-Factor Prothrombin Complex Concentrate Dosing Strategies: A Retrospective Evaluation

Area of Science:

• Hematology
• Pharmacology
• Critical Care Medicine

Background:

• 4-Factor Prothrombin Complex Concentrate (4FPCC) is approved for Vitamin K Antagonist (VKA) reversal but is increasingly used off-label for Direct Oral Anticoagulants (DOACs) and perioperative hemostasis.
• Optimal 4FPCC dosing strategies are debated, with some studies exploring lower, fixed-dose regimens.
• This study investigates 4FPCC dosing patterns and outcomes within a hospital system.

Purpose of the Study:

• To determine indication-specific 4FPCC dosing strategies.
• To evaluate the effectiveness of 4FPCC, including INR normalization, hemostatic efficacy, and patient outcomes.
• To analyze the relationship between 4FPCC dosage and mortality or renal function changes.

Main Methods:

• Retrospective cohort study of 300 patients who received 4FPCC over two years.
• Manual chart review to collect data on patient demographics, indications for 4FPCC, and administered doses.
• Analysis of secondary outcomes including INR normalization, hemostatic efficacy, in-hospital mortality, and renal function.

Main Results:

• 80% of patients received 4FPCC for anticoagulant reversal (66% VKA, 34% DOAC); 20% received it for other indications.
• 25% of patients receiving 4FPCC for anticoagulation reversal were given doses lower than recommended, and 6% received higher doses.
• Higher in-hospital mortality was observed in the group receiving higher-than-recommended doses (P = .018), attributed to patient acuity.

Conclusions:

• A significant proportion of patients received 4FPCC doses lower than recommended.
• Higher 4FPCC doses were associated with increased mortality, likely reflecting underlying patient severity rather than the dose itself.
• Further research is needed to establish optimal and effective 4FPCC dosing for various clinical indications.